Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.

Ethnopharmacological Relevance: Cissampelos pareira extract has been traditionally used in ayruveda as cardiotonic, diuretics and in heart complains but its pharmacological evaluation in thyroxin-induced cardiac hypertrophy has not yet been explored.

Aim Of The Study: The aim of this study was to assess the cardioprotective effect of C. pareira root extract in experimentally induced hyperthyroidism in rats.

Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (coxibs) and traditional NSAIDs (tNSAIDs), have been widely used for the treatment of pain and rheumatic disease. The use of NSAIDs has been linked to increased cardiovascular toxicity in both healthy individuals and patients with established cardiovascular disease. Various recently published studies have raised concerns about the cardiovascular safety of NSAIDs; this review is focused on the cardiotoxic effects of NSAIDs.

Effect of Cissampelos pareira root extract on isoproterenol-induced cardiac dysfunction.

The aim of this study was to assess the cardioprotective effect of Cissampelos pareira root extract on isoproterenol-induced cardiac dysfunction in rats. Male albino Wistar rats were randomly divided into eight groups and received either normal saline (0.5 ml/kg, intraperitoneally), isoproterenol (5 mg/kg, intraperitoneally), C.

Isoproterenol-induced cardiomyopathy in rats: influence of Acorus calamus Linn.: A. calamus attenuates cardiomyopathy.

Acorus calamus has been used as a traditional remedy since ancient days but its cardioprotective effect is not yet well characterized. The aim of this study was to assess the effect of A. calamus rhizome extract in isoproterenol-induced cardiomyopathy in rats.

RETRACTED: Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats.

The Publisher regrets that this article is an accidental duplication of an article that has already been published, http://dx.doi.org/10.

Naproxen aggravates doxorubicin-induced cardiomyopathy in rats.

Background: The repercussion of the heated dispute on cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs) led to the national and international withdrawal of several of the recently introduced coxibs. Further debate and research have highlighted risks of the classical NSAIDs too. There is much controversy about the cardiovascular safety of a nonselective NSAID naproxen (NAP) and its possible cardioprotective effect.

Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats.

The cardiotoxic effects of selective cyclo-oxygenase-2 inhibitors are well documented. Recently, concerns have been raised over the cardiovascular safety of nonselective nonsteroidal antiinflammatory drugs. The aim of this study was to assess the cardiac effects of diclofenac sodium on doxorubicin-induced cardiomyopathy in rats.

Diabetic neuropathy: therapies on the horizon.

Objectives: This is a review of emerging interventions from the recent preclinical and clinical literature that demonstrate the potential for effectiveness in the therapy of diabetic neuropathy (DN). DN is the most common complication of diabetes mellitus and up to 50% of patients with type 1 and type 2 forms have some or other form of neuropathy. The pathology of DN is characterized by progressive nerve fibre loss that gives rise to positive and negative clinical signs and symptoms such as pain, paraesthesiae and loss of sensation.